Catherine Martre

Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021.

Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021.

Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021.

Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021.